The T cell bispecific antibody, cibisatamab (CEA-TCB), is a novel immunotherapy agent that guides T cells to tumor cells that express the carcinoembryonic antigen (CEA) glycoprotein at the cell surface regardless of their T cell receptor specificity (Bacac et al., 2016; Lehmann et al., 2016; Gonzalez et al., 2019). The gene discussed is CEACAM5; the disease is neoplasm.